Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491605 | 1.00 | MEN1 (0.55) | MEN1KMT2APOLBALDH1A1CYP2D6 | |
| SCHEMBL1491681 | 0.89 | EPHX1 (0.46) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL1491678 | 0.89 | EPHX1 (0.46) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL1491527 | 0.88 | POLB (0.49) | POLBALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1491524 | 0.88 | POLB (0.49) | POLBALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8248861 | 0.85 | MEN1 (0.76) | MEN1KMT2AALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL2279040 | 0.81 | MEN1 (0.54) | MEN1KMT2AEPHX1MMP2MMP9 | |
| SCHEMBL27723672 | 0.81 | CYP2D6 (0.58) | MEN1KMT2AALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL27723671 | 0.81 | CYP2D6 (0.58) | MEN1KMT2AALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL16690715 | 0.80 | MEN1 (0.61) | MEN1KMT2AALDH1A1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-1964577-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| EP-1964577-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20090215800-A1 | Enzyme and Receptor Modulation | CHROMA THERAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| EP-1964577-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964577-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964578-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877098-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117567-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117567-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | MEN1 4467/4885KMT2A 2500/4885POLB 3917/4885 |
| US-20090215800-A1 | Enzyme and Receptor Modulation | CES1, HCAR1, DNPEP | MEN1 4467/4885KMT2A 2500/4885POLB 3917/4885 |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | MEN1 4467/4885KMT2A 2500/4885POLB 3917/4885 |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | MEN1 4467/4885KMT2A 2500/4885POLB 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.